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Abstract
Dementia with Lewy bodies (DLB) is a clinically heterogeneous disorder with a substantial burden on healthcare.
Despite this, the genetic basis of the disorder is not well defined and its boundaries with other neurodegenerative
diseases are unclear. Here, we performed whole exome sequencing of a cohort of 1118 Caucasian DLB patients,
and focused on genes causative of monogenic neurodegenerative diseases. We analyzed variants in 60 genes
implicated in DLB, Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and atypical parkinsonian or
dementia disorders, in order to determine their frequency in DLB. We focused on variants that have previously
been reported as pathogenic, and also describe variants reported as pathogenic which remain of unknown clinical
significance, as well as variants associated with strong risk. Rare missense variants of unknown significance were
found in APP, CHCHD2, DCTN1, GRN, MAPT, NOTCH3, SQSTM1, TBK1 and TIA1. Additionally, we identified a
pathogenic GRN p.Arg493* mutation, potentially adding to the diversity of phenotypes associated with this
mutation. The rarity of previously reported pathogenic mutations in this cohort suggests that the genetic overlap of
other neurodegenerative diseases with DLB is not substantial. Since it is now clear that genetics plays a role in DLB,
these data suggest that other genetic loci play a role in this disease.
Introduction
Dementia with Lewy bodies (DLB) is a neurodegenera-
tive disease that shares clinical and pathological features
with both Parkinson’s disease (PD) and Alzheimer’s disease
(AD). A disease most often occurring in the elderly demo-
graphic, it exhibits a varied clinical presentation that can in-
clude dementia, parkinsonism, visual hallucinations, REM
sleep behavior disorder, fluctuations in attention and alert-
ness, as well as autonomic and psychiatric dysfunction [49],
all described as clinical features of underlying synucleinopa-
thy. Similar to PD, the pathological hallmark of DLB is ac-
cumulation of alpha-synuclein in Lewy bodies (LBs) and
Lewy neurites, leading to consideration of these conditions
as different ends of the same clinico-pathological spectrum.
Lewy-related pathology in DLB can be found not only in
the brainstem, but also widespread in limbic and/or neocor-
tical regions [47]. Alzheimer pathology in the form of
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amyloid plaques and tau neurofibrillary tangles are fre-
quently found at autopsy [17].
At present, knowledge of the genetic etiology of DLB
is limited. Families with the disorder are rare, and SNCA
multiplications and point mutations have been shown to
cause disease in multiplex families of mixed Parkinson’s
disease and dementia [31, 63, 77]. Variants in PRNP [38]
and SNCB [55] have been reported in DLB, but their
pathogenicity has been questioned due to lack of replica-
tion, lack of segregation [55], or presence in healthy con-
trols [8]. DLB shares risk loci that are associated with
AD or PD, and we have recently shown the genetic cor-
relation between DLB and PD, and DLB and AD, is ap-
proximately equal when disregarding APOE [26]. The
APOE ε4 allele strongly predisposes to the development of
the disorder [13, 57, 64, 69], as do certain variants in the
GBA gene [53]. A non-synonymous variant in PLCG2 has
been proposed to confer protection from AD [62], and
more recently, DLB and frontotemporal dementia (FTD)
[71]. An association at the SNCA locus was identified,
which, interestingly, shows a differential association profile
in DLB than that seen in PD [13]. Furthermore, the first
genome-wide association study (GWAS) was recently pub-
lished, analyzing the genotyping data from 1743 DLB pa-
tients, a proportion of whom (745 samples) are also
included in this study. In a two-stage study design, the asso-
ciations at APOE, GBA and SNCA were replicated, and
novel loci reached suggestive levels of association [27]. It
has been proposed that rare variants in AD and PD causing
genes may also play a role in sporadic DLB. However, these
studies have been small, with sample sizes of approximately
100 cases [36, 37, 51]; it is thus uncertain whether these
findings are merely coincidental.
We performed exome sequencing of over 1000 DLB
patients to investigate the role of genetic variants in not
only AD and PD genes, but additionally in a collection
of approximately 40 disease genes established as causa-
tive of neurodegenerative diseases. The genetic variants
studied were those previously implicated in FTD with or
without amyotrophic lateral sclerosis (ALS); atypical par-
kinsonian disorders; and disorders with dementia as a
presenting feature.
As DLB is a heterogeneous disorder, and has overlap-
ping features with other diseases, accurate diagnosis relies
on the combination of clinical and pathological assess-
ments. To mitigate this issue as much as possible, the
DLB patients included in this study had a neuropatho-
logical diagnosis of DLB.
Methods
Cohort studied
We studied 1118 patients neuropathologically diagnosed
according to the 2005 McKeith diagnosis guidelines [49],
as meeting the criteria for ‘intermediate’ or ‘high’
likelihood DLB and self-reported as Caucasian. The
mean age at death in the cohort was 78.8 (±8.4) years
and the male to female ratio was 1.5.
Exome sequencing and data analysis
DNA was extracted from the cerebellum or frontal cortex
using standard methods [75]. Exome sequencing was per-
formed using Illumina’s Nextera Rapid Expanded Exome
capture (62Mb), or Agilent SureSelect Exome Capture Kit
(v4) and sequenced on Illumina’s HiSeq2500 using 100 bp
paired-end reads. On target average coverage of at least
30x was obtained for all included samples. Data analysis
was performed according to standard GATK (v3) best
practices [50] using a single informatics pipeline and per-
forming joint variant calling of single nucleotide variants
(SNVs) and short insertions and deletions (indels) across
all samples. In brief, sequencing reads were aligned to the
human reference genome (GRCh37/hg19) using bwa-
mem (v0.7.12), duplicate reads were flagged using sambla-
ster (v0.1.21), and realignment around indels and base
quality scores were recalibrated using GATK. Variant re-
calibration was performed using GATK’s variant quality
score recalibration (VQSR) [21, 70]. Variants that did not
meet the VQSR threshold of 99.9 were excluded. Individ-
ual genotypes with a phred-scaled quality score below 20
and with coverage below 8 were set to missing. Variants
were included only if they had a high call rate in both cap-
ture kits (genotyped in ≥90% of samples). Annotation of
variants was performed with snpEff (v4.2) [15] and
dbNSFP v2.9 [44] using GRCh37/hg19 as reference.
Sample quality control (QC)
Sample quality control metrics were generated using
PLINK 1.9 [58]. Population structure was analysed using
principal component analysis, and samples that did not
cluster with the European population of the 1000 Genomes
dataset were removed from analysis. Concordance between
reported and genotype sex was performed for each sample
to remove those with a discordant sex assignment. Samples
with inconsistent heterozygosity rates, or that were shown
to be related or duplicated were excluded. Due to linkage
disequilibrium, population structure and genotyping error,
we removed an individual from a pair of samples using a
proportion of identity by descent threshold of ≥0.1875 [3].
After QC measures, we analyzed variants from 1004 DLB
patients. The locations from which the DLB samples were
sourced can be found in Additional file 1: Table S1.
Neurodegenerative disease genes
Fifty-seven genes were selected based on their role in
monogenic forms of neurodegenerative diseases including
AD, PD, FTD and related Mendelian disorders featuring
parkinsonism or dementia. Due to its relevance to DLB,
we also report on variants in GBA and APOE, as well as
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the PLCG2 p.Pro522Arg variant. A full list of the studied
genes can be found in Additional file 2: Table S2.
We focused on variants that were amino acid chan-
ging; or that fell in splice donor/acceptor sites; in splice
regions, or in 5′ or 3′ untranslated regions.
A literature search was conducted for each disease-
causing gene studied in order to identify previously re-
ported pathogenic mutations. This included primary lit-
erature reports; supplementary information; the Human
Gene Mutation Database [66]; the Online Mendelian In-
heritance in Man website [2]; the AD & FTD, and PD
mutation databases [20]; and Clinvar [39]. Population
variant frequency was determined using gnomAD (v2.1),
a genomic database consisting of variants from 125,748
exomes and 15,708 genomes [34, 41].
The maximum frequency that a known pathogenic vari-
ant occurs in a large cohort of a disease of interest allows
for an estimation of the maximum tolerated frequency of a
pathogenic variant for that disease [74]. As the genetics of
DLB is yet to be fully delineated, we used Alzheimer’s dis-
ease to estimate a maximum tolerated allele count for a
pathogenic variant to occur in the gnomAD database, im-
plemented using the alleleFrequencyApp http://cardiodb.
org/allelefrequencyapp/ [74]. This was used as a conserva-
tive approximation of maximum tolerated variant frequen-
cies for pathogenic mutations in the general population for
a disease such as AD.
Reported variants were also analysed for their frequency
in 432 control individuals from the Healthy Exomes (HEX)
dataset, who died aged 60 or over, without any disease-
associated neuropathology [29, 28].
APOE genotyping
Given the difficulty in sequencing the APOE locus, the
APOE haplotype was confirmed in samples where DNA
was available (n = 758 samples). APOE haplotype geno-
typing was conducted using enzyme restriction, as previ-
ously described [29].
Sanger sequencing
Candidate variants were confirmed by Sanger sequencing
when DNA was available. DNA was amplified by polymer-
ase chain reaction using Roche FastStart PCR Master Mix
(Roche Diagnostics Corp) and sequenced with Applied
Biosystems BigDye terminator version 3.1 sequencing
chemistry in an ABI3730XL genetic analyzer as per manu-
facturer’s instructions (Applied Biosystems). Primers are
available upon request. The sequences were analysed
using Sequencher software version 4.2 (Gene Codes).
Results
We performed a detailed analysis of the genetic variability
of 57 genes shown previously to cause neurodegenerative
diseases in over 1000 DLB cases. Furthermore, we also
report on GBA and APOE, well established risk genes for
DLB, as well as the recently reported protective PLCG2
p.Pro522Arg variant.
We identified a pathogenic nonsense mutation in GRN,
p.Arg493* (ENST00000053867), in one patient. This vari-
ant was confirmed by Sanger sequencing. In addition, we
identified previously reported mutations that, due to their
low frequency in the general population, have uncertain
clinical significance (Table 1). No previously reported
pathogenic homozygous variants were identified in genes
that cause neurodegenerative disease with autosomal re-
cessive inheritance. As the data was not phased, com-
pound heterozygous variants could not be completely
assessed.
GRN p.Arg493*
The patient with the p.Arg493* GRN mutation had a med-
ical history that included a stroke, and previous surgical
evacuation of a subdural haematoma, as well as a family
history of AD in a parent and a sibling, with onset in the
seventh decade. The presenting symptom was episodes of
confusion, and a CT scan showed moderate cerebral and
cerebellar atrophy with a lacunar infarct in the left external
capsule. Subsequent symptoms included memory loss, dis-
orientation, altered gait, stooped posture, right-sided rigid-
ity and visual hallucinations. Impaired smooth pursuit, left
hemiparesis, left spasticity, right-sided rigidity, and a slight
parkinsonian tremor of the left hand were also reported.
The patient was severely demented and scored 3/30 on the
Mini Mental State Examination (MMSE) in an assessment
conducted at 83 years, approximately 2 years before death.
Macroscopically, the right convexity of the brain showed
very marked asymmetrical atrophy of the frontal, temporal
and parietal lobes, with knife-edge atrophy at the frontal and
temporal poles, and mild atrophy of the right occipital lobe.
There were no focal lesions. Pathological examination with
immunohistochemical staining for alpha-synuclein protein
showed a single LB in the substantia nigra; very infrequent
Lewy bodies in multiple cortical areas; sparse LBs in the an-
terior cingulate, entorhinal and transentorhinal cortices; and
no LBs in the amygdala. Thioflavin S methods showed fre-
quent diffuse amyloid plaques in neocortical areas. Very in-
frequent neurofibrillary tangles were present in the nucleus
basalis of Meynert, hypothalamus and entorhinal cortex,
and were absent from all neocortical areas examined. Immu-
nohistochemical staining for abnormal tau protein identified
frequent dot-like features and diffusely stained neurons in
the entorhinal cortex, transentorhinal cortex, CA1 and subi-
culum of the hippocampus and the parahippocampal gyrus.
There were sparse argyrophilic grains in the amygdala, ento-
rhinal cortex and area CA1 of the subiculum. Immunohisto-
chemical staining for ubiquitin showed moderate densities
of short neuropil threads and dots, as well as sparse to mod-
erate densities of small cytoplasmic inclusions in layer II of
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frontal and temporal neocortical regions. Following the
identification of the mutation, the sample was stained for
TDP-43 and revealed inclusions in frontal and temporal
lobes. Sections stained immunohistochemically for phos-
phorylated TDP-43 protein showed immunoreactive dys-
trophic puncta, neurites and perikaryal cytoplasmic
inclusions within layer II of frontal and temporal neocortical
areas, as well as the amygdala, hippocampal CA1 region,
and entorhinal cortex. These features reached moderate to
frequent densities in the frontal and temporal neocortex.
Established risk factors for DLB
No homozygous Gaucher disease causing variants were
identified in GBA. Table 2 details variants found in GBA
that had a call-rate of 90% or greater. Two variants,
p.Glu365Lys and p.Asn409Ser were over-represented in
DLB compared to the gnomAD database. Of note, 2
homozygous carriers of p.Glu365Lys were identified and
a novel variant, p.Asn409del, was identified in 1 patient
in the cohort.
APOE haplotypes were independently genotyped in 758
DLB samples where DNA was available. Of this subset of
samples, the ε4 allele frequency was 48.6%, in keeping with
the prevalence of this allele in previous reports [64, 69].
Potentially pathogenic variants
We used Alzheimer’s disease genetics as a model in order
to apply an approximate threshold for the tolerated occur-
rence of pathogenic AD mutations in gnomAD. We applied
an AD prevalence of 1/79 (Alzheimer Society Dementia re-
port, 2014); a maximum estimated disease-causing MAF of
0.0012; and a very conservative penetrance threshold of 0.5.
The maximum tolerated frequency for a pathogenic allele
for AD using the allele number of a variant genotyped in
the entire gnomAD European (non-Finnish) population
was 1.5556 × 10− 5, or five alleles. This is a very conservative
approximation, likely to be too high since AD is more
prevalent than DLB, however since the genetic architecture
of DLB still remains largely unresolved, we used AD as an
approximation. In Table 1 we describe previously reported
variants of unknown clinical significance that were present
in 5 or less Europeans in the gnomAD database. None of
these variants were detected in the control individuals from
the HEX dataset. These variants were identified in APP,
CHCHD2, DCTN1, GRN, MAPT, NOTCH3, SQSTM1,
TBK1 and TIA1. Variants were reported in Table 1 if the
evidence for pathogenicity was moderate, such as having
unproven segregation with disease; eliciting a different
amino acid change than was previously reported; identified
in a gene that has not been replicated as causative for dis-
ease; or if the variant has also been identified in a control
subject. Table 1 also shows variants not present in Euro-
peans in gnomAD that affect the same or an adjacent
amino acid as previously reported in disease. Table 3 lists
variants identified in multiple DLB cases and with 5 or less
alleles in gnomAD.
Variants that have previously been reported in disease,
but were more frequent in the general population, thus
less likely to be fully penetrant, disease-causing alleles,
are reported in Additional file 3: Table S3. These include
variants such as SNCA p.His50Gln, which is present in
19 Europeans in gnomAD, and whose pathogenicity has
been disputed [10].
Genes previously reported in DLB
We investigated variants in genes that have been re-
ported as causative of DLB - PRNP and SNCB - as well
as a gene in which a variant was recently reported as
protective for DLB - PLCG2.
The previously identified PRNP p.Met232Arg [38]
variant was not present in our cohort, and there were no
other previously reported pathogenic variants in PRNP
in our data. It is therefore unlikely that PRNP mutations
cause sporadic DLB in the European population.
The SNCB p.Val70Met and p.Pro123His variants reported
to predispose to DLB [55] were also not found in our cohort
of DLB cases, suggesting that if they play a role in DLB, they
may be population specific risk factors. In our cohort, no
non-synonymous variants were found in the SNCB gene,
even though the entire gene was adequately covered.
A variant in PLCG2, p.Pro522Arg, has been reported to
reduce the risk of DLB, AD and FTD [71]. This variant
was identified in 18 DLB cases (MAF 0.0089), which is
similar to the frequency found in gnomAD non-Finnish
Europeans (MAF 0.0087).
TREM2
TREM2 is the second strongest genetic risk factor for
AD, an effect largely driven by the p.R47H variant. In our
data, the p.Arg47His variant, which was successfully se-
quenced in 667 of the 1004 samples, had a MAF 0.00299,
which is similar to the frequency in NFEs in gnomAD
(MAF 0.002466). The p.Arg62His variant also had a simi-
lar MAF in DLB (0.0142), compared to Europeans in the
gnomAD database (0.0112). Likewise, the frequency of
p.Thr96Lys and p.Leu211Pro variants was similar in DLB
patients and gnomAD, (MAF 0.000991 versus 0.00101,
and MAF 0.000992 versus 0.00113), respectively. No
homozygous variants in TREM2 were identified.
Discussion
We present a comprehensive analysis of rare genetic
variability in an extensive number of neurodegenerative
disease-causing genes in a large cohort of patients diag-
nosed with DLB. We used state-of-the-art analytical ap-
proaches with well-established quality control criteria
that allowed us to identify genetic variability and esti-
mate its contribution to disease.
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Mutations in GRN cause FTD [7, 19], and the most
commonly reported pathogenic mutation in GRN is
p.Arg493* [59]. The patient described here lacked promin-
ent clinical signs of FTD, such as changes in behavior, per-
sonality, or language impairment. Severe dementia,
parkinsonism and visual hallucinations were present, and
led to the suggested clinical diagnosis of Alzheimer’s dis-
ease or mixed vascular dementia, with a final neuropatho-
logical diagnosis of Alzheimer’s disease, dementia with
Lewy bodies and argyrophilic grain disease. Substantial
phenotypic variability has been described in patients with
a GRN p.Arg493* mutation. In 34 patients identified with
this mutation, 25 had a diagnosis of FTD; 4 of primary
progressive aphasia; 3 of corticobasal syndrome and 3 of
Alzheimer’s disease. Age at onset ranged from 44 to 69,
and the most common initial symptom was a change in
personality or executive dysfunction (25/33 patients), with
subsequent language impairment occurring in 26 of 33 pa-
tients. Fourteen out of thirty patients had parkinsonism
and 10% had visual hallucinations [59]. This mutation has
also been found in 4 patients with sporadic Alzheimer’s
disease [24].
An overlap between FTD and DLB has been shown both
clinically and neuropathologically. Several patients have
been identified that simultaneously met clinical criteria for
both FTD and DLB [16, 52], or that presented clinically
with FTD, but at autopsy had DLB [11, 61]. Concomitant
TDP-43 and alpha-synuclein pathology can be found in
27–60% of DLB cases at autopsy [4, 17, 48]. In general,
GRN mutations result in disease with clinical heterogeneity
[40, 72, 73], and it is possible that overlaps between DLB
and FTD may be connected to variation in GRN. It is also
possible that hallucinations and delusions in GRN carriers
may cause a misdiagnosis of DLB [9]. An FTD case harbor-
ing the GRN p.Thr382fs mutation showed a phenotype re-
sembling DLB, with fluctuations in cognition,
parkinsonism and visual hallucinations [5]. Furthermore,
alpha-synuclein and TDP-43 pathologies were found in a
subset of brains of patients with a GRN mutation [42]. A
small study in 58 DLB cases showed that together, rare var-
iants in GRN are associated with DLB [37], although this is
yet to be independently replicated. A recent study identi-
fied 9 heterogeneous FTLD cases with coexisting Lewy
body pathology Braak stage ≥ IV, comprising 7% of the co-
hort. Two of the 9 cases had a secondary diagnosis of DLB,
and a further 2 had GRN mutations [25]. Progranulin and
β-amyloid have been shown to co-localize in plaques in
DLB, suggesting a possible biological association between
these two aggregated proteins [60]. However, there are
often multiple concomitant pathologies that are identified
in neurodegenerative disease, and so the observation of
TDP-43 with Lewy and amyloid pathology could simply be
coincidental multi-morbidity of simultaneous pathologies
that coexist in the ageing brain [6]. After the identification
of the GRN mutation, additional clinicopathological infor-
mation was reviewed to assess this case. The histopatho-
logical findings of the p.Arg493* carrier revealed Lewy
bodies; amyloid plaques; argyrophilic grains; ubiquitin posi-
tive inclusions; tau staining, and when reanalysed, TDP-43
pathology. The medical history reported the occurrence of
a stroke, which was also confirmed by a CT scan, however
no further clinical information was available. Taken to-
gether, these facts add to the difficulty in classifying these
more complex forms of disease. Particularly in archive
cases where the neuropathology assessment did not origin-
ally include staining for TDP-43.
We identified possible pathogenic variants in other genes
linked to the FTD-ALS spectrum of disease. A variant in
TIA1, p.Pro362Leu, suggested to be causative of ALS/FTD,
was found in 1 DLB patient in the cohort. TIA1 encodes
an RNA-binding protein, and this variant was reported in a
pair of second degree relatives with ALS/FTD, as well as a
clinically symptomatic, but non-demented relative. An in-
creased burden of rare heterozygous TIA1 mutations in a
larger ALS/FTD cohort was reported [45]. In two neuro-
pathologically diagnosed DLB cases, we found two variants
in TBK1 that affected the same amino acid: p.Arg384Trp
and p.Arg384Gln. This amino acid has been found to be al-
tered in a sporadic Sardinian ALS case (p.Arg384Thr) [12]:
a variant not present in gnomAD, but whose pathogenicity
is unconfirmed. It is intriguing that two DLB cases were
identified with variants that affect the same amino acid.
Table 3 Variants found in more than 1 DLB case, that were present in 5 or less individuals from the gnomAD exome dataset of
non-Finnish Europeans
Gene Transcript Variant Number of DLB cases GnomAD NFE AC (Total NFE AN)
PARK2 ENST00000366898 p.Gln440Arg 2 1 (112822)
VPS13C ENST00000261517 p.Ile288Met 2 4 (112094)
TUBA4A ENST00000248437 p.Val181Met 2 5 (113764)
DNAJC6 ENST00000371069 p.Val632Ala 2 0 (83222)
VPS35 ENST00000299138 p.Arg499His 2 4 (113646)
All variants were identified in the heterozygous state. gnomAD NFE Non-Finnish European, AC Allele Count, AN Allele Number
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These variants are present in gnomAD (MAFs 0.0000213
and 0.0000851, respectively). At present, their contribution
to DLB is unclear.
From the perspective of AD related genetics, we identified
a variant of unknown significance in APP - p.Glu674Lys -
in a DLB case, a substitution of a negatively charged amino
acid to a positively charged amino acid at the 3rd residue of
the ß-amyloid peptide. This variant was not present in the
gnomAD database, and affects an adjacent amino acid to
that previously described. The p.Ala673Val was shown to
cause early onset Alzheimer’s disease in the homozygous
state, whereas heterozygous individuals in the family were
unaffected [22]. A different amino acid change at the same
position, p.Ala673Thr, has been reported in a patient with-
out AD [56], and predicted as non pathogenic due to non
segregation with disease in a family [18]. Furthermore, this
variant was shown to be protective against Alzheimer’s dis-
ease in the Icelandic population, where it resulted in a re-
duction of beta-secretase cleavage in vitro [32].
We have also looked at strong risk modulating genes:
GBA, TREM2, APOE and PLCG2. If at GBA and APOE
we saw evidence of increased frequency in the previously
reported variants, we did not observe such a finding at
TREM2 or PLCG2, with both showing frequencies that
are identical to those found in the general population.
We have also identified a number of possible pathogenic
mutations in several other genes studied here (Table 1).
The design of this study does not allow variant pathogen-
icity to be unequivocally established, and, in this way, we
report these variants to allow future studies to attempt
confirmation of these findings.
In summary, we provide the first large-scale
characterization of rare genetic variability in the most
relevant neurodegenerative disease-causing genes in DLB.
Our findings suggest that mutations in genes known to
cause other neurodegenerative diseases are not a common
cause of DLB.
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1186/s40478-020-0879-z.
Additional file 1: Table S1. Sources of samples. Research groups,
clinical teams and brain banks where the DLB samples included in this
study were collected from.
Additional file 2: Table S2. Neurodegenerative disease-causing genes
and DLB risk genes analysed in this study. Genes known to cause neuro-
degenerative diseases are presented according to the mode of inherit-
ance of the respective mendelian disease. Genes such as PARK2, FBXO7,
SYNJ1, and DNAJC6, among others, are commonly referred to as parkin-
son’s disease genes, although the clinical and pathological characteristics
may be atypical in some cases. FTD/ALS - frontotemporal dementia/
Amyotrophic lateral sclerosis, CADASIL - Cerebral arteriopathy, autosomal
dominant, with subcortical infarcts and leukoencephalopathy, CARASIL -
Cerebral arteriopathy, autosomal recessive, with subcortical infarcts and
leukoencephalopathy *Both TMEM230 and DNAJC13 have been hypothe-
sised to be the cause of Parkinson’s disease in the same family.
Additional file 3: Table S3. Variants identified in the studied DLB
cohort that have been previously reported in disease and have a
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